Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phenylalanine hydroxylase (PAH) is an enzyme encoded by the PAH gene. Deficiency or mutations in the PAH gene result in phenylketonuria (PKU), a metabolic disorder characterized by elevated levels of phenylalanine in blood and tissues. Gene transfer strategies aim to introduce functional copies of the human PAH gene into cells lacking normal activity, offering a potential cure for PKU at its genetic root rather than managing symptoms through dietary restriction alone. Preclinical studies demonstrate feasibility using both plasmid-based and viral vector-mediated delivery systems in cell culture models and animal hepatocytes. Ongoing research aims at translating these findings toward clinical application.
Introduction of functional PAH gene to restore phenylalanine hydroxylase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phenylalanine Hydroxylase Gene Transference.